
    
      This is a single-arm, multicenter Phase 2 study to evaluate the efficacy and safety of the
      CAR-T for Stomach Cancer. The study will be conducted using a phaseⅠ /Ⅱ design.The study will
      have the following sequential phases: Part A(screening leukapheresis, cell product
      preparation, and cytoreductive chemotherapy) and Part B(treatment and follow-up). The
      follow-up period for each participant is approximately 35 months after the final CAR-T
      infusion.The total duration of the study is expected to be approximately 3 years. A total of
      19 patients may be enrolled over a period of 3 years.
    
  